United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenilearthritis naproxen tablets are also indicated: - for relief of the signs and symptoms of tendonitis - for relief of the signs and symptoms of bursitis - for relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary dysmenorrhea naproxen tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ see warnings and precautions (5) ] celecoxib is indicated for relief of the signs and symptoms of oa [ see clinical studies (14.1) ] celecoxib is indicated for relief of the signs and symptoms of ra [ see clinical studies (14.2) ] celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] celecoxib is indicated for the relief of signs and symptoms of as [ see clinical studies (14.4) ] celecoxib is indicated for the management of ap in adults [ see clinical studies (14.5) ] celecoxib is indicated for the treatment of pd [

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen tablets and other treatment options before deciding to use naproxen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naproxen tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritits naproxen tablets are also indicated: - for relief of the signs and symptoms of tendonitis - for relief of the signs and symptoms of bursitis - for relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary  dymenorrhea naproxen tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen tablets should not be given to patients who have experienced asthma, urticaria, or al

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ see warnings and precautions (5) ] celecoxib capsules are indicated for relief of the signs and symptoms of oa [ see clinical studies (14.1) ] celecoxib capsules are indicated for relief of the signs and symptoms of ra [ see clinical studies (14.2) ] celecoxib capsules are indicated for relief of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] celecoxib capsules are indicated for the relief of signs and symptoms of as [ see clinical studies (14.4) ] celecoxib capsules are indicated for the management of ap in adults [ see clinical studies (1

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen is also indicated: - for relief of the signs and symptoms of tendonitis - for the relief of the signs and symptoms of bursitis - for the relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary dysmenorrhea naproxen is contraindicated in patients with known hypersensitivity to naproxen and naproxen sodium. naproxen should not be given to patients who have experienced asthma, urticaria, or allergic-type rea

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen tablets and other treatment options before deciding to use naproxen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen tablets are also indicated: - for the relief of the signs and symptoms of tendonitis - for the relief of the signs and symptoms of bursitis - for the relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary dysmenorrhea naproxen tablets are contraindicate

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium delayed-release tablets, are indicated: - for relief of signs and symptoms of osteoarthritis - for relief of signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphyla

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). culture and susceptibility testing appropriate

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within 4 weeks. some patients may require an additional 4 weeks of therapy. omeprazole delayed-release capsules, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to one year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules, in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.1) and dosage and administration (2)]. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in pati

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - the optimal duration of clopidogrel bisulfate therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel bisulfate has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not), and other vascular death. clopidogrel bisulfate is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel bisulfate is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see adverse reactions (6.2)] . reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m2 basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. there are, however, no adequate and well-controlled studies in pregnant women. beca